Last update July 1, 2015


Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Polypeptide with anti-microbial activity that is produced by strains of Bacillus licheniformis or Bacillus subtilis. Indicated for topical use (high nephrotoxicity with systemic use)

Not absorbed through skin, mucosa or intestinal tract. When orally taken it is destroyed by the gut with no pass into the blood stream.

Preferably, avoid it on the breast or clear it out before nursing. Avoid use of creams, gels and other topical medication containing paraffin (petroleum-derived mineral oil) in order to avoid the risk of absorption by the child.

The WHO Model List of Essential Medicines 2002 rates it as compatible with breastfeeding.


We do not have alternatives for Bacitracin-Zinc since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Bacitracin-Zinc in other languages or writings:


Bacitracin-Zinc belongs to this group or family:


Main tradenames from several countries containing Bacitracin-Zinc in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 1460 daltons


  1. Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Fessler S, Windbichler G, Zeimet A, Ulmer H, Siegl H, Rieger K, Concin H, Grob K. Mineral oil paraffins in human body fat and milk. Food Chem Toxicol. 2008 Abstract
  2. Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin. 2006 Abstract
  3. WHO Pharmaceuticals Newsletter. 2005 Full text (link to original source) Full text (in our servers)
  4. Noti A, Grob K, Biedermann M, Deiss U, Brüschweiler BJ. Exposure of babies to C15-C45 mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003 Abstract
  5. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)
  6. LONGACRE AB, WATERS RM. Observation on absorption of bacitracin; blood levels following all administration. Surg Gynecol Obstet. 1951 Abstract
  7. ZINTEL HA, MA RA, et al. The absorption, distribution, excretion and toxicity of bacitracin in man. Am J Med Sci. 1949 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM